Duopharma Biotech, a pharmaceutical company in Malaysia, recently marked a significant milestone with the unveiling of its new regional office in German Centre, Singapore reinforcing its commitment to the Singaporean market.
The Singapore office has played a key role in charting Duopharma Biotech’s regional and international footprint, driving business activities and opportunities.
While Duopharma Biotech has since expanded into the Philippines in 2007 and established a wholly-owned subsidiary in Indonesia in April 2023, Singapore remains a key hub for the company. As the key growth hub, the new office also reflects Duopharma Biotech’s increasing footprint thus strengthening its position in the region.
Duopharma Biotech Group Managing Director Leonard Ariff Abdul Shatar commented, “Our key objective is ensuring that we meet the needs of patients and consumers by making our products available, accessible and affordable to a wide and diverse range of customers, including offerings in preventive medicine and early detection. And for the added benefit of our Muslim patients and consumers, all products manufactured in our facilities are certified Halal by the Department of Islamic Development Malaysia (JAKIM). In fact, Duopharma Biotech is the first producer of the world’s first halal-certified cancer drug.”
Duopharma Biotech has a portfolio of 78 products sold in Singapore comprising ethical and consumer healthcare products. The Company is active in the market segments of Private GP, Hospital, Retail, Government and others.
Looking ahead, in line with its commitment to affordability and accessibility, Duopharma Biotech is targeting to expand its portfolio in Singapore, focusing on introducing its line-up of biosimilars, as well as sustainable plant-based functional and wellness foods and cosmeceuticals, in addition to other segments such as Medical Devices, Commercial Digital Integration, Innovative Healthcare Solutioning, Telemarketing and more.
This office will serve as Duopharma Biotech’s operation hub, facilitating enhanced customer support and fostering closer collaborations with local partners and driving regional and global business activities, capitalising on Singapore’s reputation as a healthcare leader in the region.
.
